CLAIMS

1. Use of a combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist and an interferon (IFN) agent, for preparing a medicament for use for treating a HBV infection,

wherein the TNFRSF agonist comprises or consists of TWEAK, and

wherein the IFN agent is IFNα, IFNβ, IFNγ or IFNλ.

2. Use of a bifunctional immunostimulatory fusion protein for preparing a medicament for use for treating a HBV infection, the bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist, an interferon (IFN) agent, and a linker,

wherein the TNFRSF agonist comprises or consists of TWEAK, and

wherein the IFN agent is IFNα, IFNβ, IFNγ or IFNλ.

3. The use according to claim 1 or 2, wherein the IFN agent is IFNβ or IFNγ.

4. The use according to any one of claims 1 to 3, wherein the IFN agent is IFNβ.

5. The use according to claim 1 or 2, wherein the IFN agent is IFNα.

6. The use according to any one of claims 1 or 3 to 5, wherein the TNFRSF agonist and the IFN agent are comprised in a single pharmaceutical composition.

7. The use according to any one of claims 1 or 3 to 5, wherein the TNFRSF agonist and the IFN agent are comprised in distinct pharmaceutical compositions.

8. The use according to any one of claims 1 to 7, wherein the TNFRSF agonist is TWEAK or a fusion protein comprising TWEAK.

9. The use according to claim 8, wherein the fusion protein comprising TWEAK is Ig-TWEAK.

10. The use according to claim 8 or 9, wherein TWEAK is represented by SEQ ID NO: 3.

11. The use according to any one of claims 2 to 5, wherein the linker is a peptide linker incorporating a multimerization domain.

12. The use according to claim 11, wherein the multimerization domain is selected among a tenascin trimerization motif, a collectin trimerization domain, streptavidin, an IgE heavy-chain domain 2 (EHD2), an IgM heavy-chain domain 2 (MHD2), an IgG heavy-chain domain 3 (GHD3), an IgA heavy-chain domain 3 (AHD2), an IgD heavy-chain domain 3 (DHD3), an IgE heavy-chain domain 4 (EHD4), an IgM heavy-chain domain 4 (MHD4), an Fc domain, an uteroglobin dimerization domain and a leucine zipper (LZ) domain.

13. A pharmaceutical composition comprising:

a TNFRSF agonist; and

an interferon (IFN) agent

wherein the TNFRSF agonist comprises or consists of TWEAK, and

wherein the IFN agent is IFNα, IFNβ, IFNγ or IFNλ.

14. A pharmaceutical composition comprising a bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist, an interferon (IFN) agent, and a linker,

wherein the TNFRSF agonist comprises or consists of TWEAK, and

wherein the IFN agent is IFNα, IFNβ, IFNγ or IFNλ.

15. A combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist and an interferon (IFN) agent, for use for treating a HBV infection,

wherein the TNFRSF agonist comprises or consists of TWEAK, and

wherein the IFN agent is IFNα, IFNβ, IFNγ or IFNλ.

16. A bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist, an interferon (IFN) agent, and a linker, for use for treating a HBV infection,

wherein the TNFRSF agonist comprises or consists of TWEAK, and

wherein the IFN agent is IFNα, IFNβ, IFNγ or IFNλ.

17. The pharmaceutical composition according to claims 13 or 14, the combination according to claim 15 or the bifunctional immunostimulatory fusion protein according to claim 16, wherein the IFN agent is according to any one of claims 3 to 5.

18. The pharmaceutical composition according to claims 13 or 14, the combination according to claim 15 or the bifunctional immunostimulatory fusion protein according to claim 16, wherein the TNFRSF agonist is according to any one of claims 8 to 10.